Calcimedica Inc (CALC)

$0.59 0.00 (-0.54%)
Market Cap 9.21M
Revenue (ttm) 0.00
Net Income (ttm) -29.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.19
Volume 171,800
Avg Vol 1,508,806
Day's Range N/A - N/A
Shares Out 15.74M
Stochastic %K 44%
Beta 0.76
Analysts Strong Sell
Price Target $10.33

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 5500
Address:
505 Coast Boulevard South, Suite 307, La Jolla, United States
Butterflies5
Butterflies5 Apr. 3 at 12:25 AM
$CALC Oppenheimer has a $10 price target reduced from $20 based upon an issue that's been proven to be incorrect. So why are we at $0.59?
0 · Reply
keokeostwiz
keokeostwiz Apr. 2 at 11:50 AM
$CALC Nothing has changed from the $7 handle before being HIT with unsubstantiated safety concerns during trial.......24% insider ownership consumed by seeking new finance agreement.....when news appears out of nowhere volume will surge and price will retrace suddenly.....facing June FDA acceptance of P3 trial design as expecting some kind of financial outcome before that crucial timeline.....the science is stellar and the pipeline loaded with outstanding candidates for development.....once finances secured CALC will reward shareholders handsomely and continue pursuit of pipeline development.....JMO
1 · Reply
Super_Marioo
Super_Marioo Apr. 1 at 5:23 PM
$CALC - nice upward stair pattern on daily chart. going up! let’s take the faster escalator next toward $1.
0 · Reply
OffComesTheShirt
OffComesTheShirt Apr. 1 at 3:20 PM
$CALC 11% Off Comes The Shirt
0 · Reply
pablo4
pablo4 Apr. 1 at 2:55 PM
$CALC just need that volume....then zoom, IMO.
0 · Reply
pablo4
pablo4 Mar. 31 at 7:03 PM
$CALC I have a feeling that volume is going to show up suddenly and price will loose. CALC closed its gap at .507 earlier today that was opened a couple of weeks or so back on the day of its ER that, along with earnings, disclosed that there were no safety issues found in the Kourage trial after all. IMO
0 · Reply
Butterflies5
Butterflies5 Mar. 31 at 1:12 AM
$CALC Oppenheimer lowers its target price from $20 down to $10 and we're trading at 52 cents Make it make sense
0 · Reply
keokeostwiz
keokeostwiz Mar. 30 at 4:24 PM
$CALC The liquidity problem will lead management toward a material event involving a finance deal, partnership or attracting a buyer for a valuable late stage pipeline as the company could get 150M - 200M in a sale event. Any of the above scenarios would present a serious problem for the shorts attempting to suppress price. Management is heavily invested and would not benefit from a heavily diluted cash raise leading rational decision toward securing a cash rich partner or sale . I believe management will protect their huge investment by securing a financial arrangement beneficial to shareholders and not reflecting a .54 cent share value.......JMO
0 · Reply
Eli18222
Eli18222 Mar. 27 at 4:41 PM
$CALC interesting actions recently
1 · Reply
Super_Marioo
Super_Marioo Mar. 26 at 7:58 PM
$CALC - not sure when but we are due for a MASSIVE pop for multiple reasons! $3 was the floor with before the FALSE safety issue that has now been confirmed. I will wait it out. $5-$10 was where it was heading with positive pipeline updates.
1 · Reply
Latest News on CALC
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

Mar 3, 2026, 7:00 AM EST - 4 weeks ago

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

Jan 28, 2026, 11:48 AM EST - 2 months ago

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

Jan 28, 2026, 7:00 AM EST - 2 months ago

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Nov 12, 2025, 7:01 AM EST - 5 months ago

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Nov 12, 2025, 7:00 AM EST - 5 months ago

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Nov 10, 2025, 7:00 AM EST - 5 months ago

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Oct 14, 2025, 7:00 AM EDT - 6 months ago

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 7 months ago

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2025, 7:00 AM EDT - 8 months ago

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 7:00 AM EDT - 9 months ago

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

Jun 25, 2025, 7:00 AM EDT - 10 months ago

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

Jun 12, 2025, 7:00 AM EDT - 10 months ago

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

May 14, 2025, 7:00 AM EDT - 11 months ago

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentations at Upcoming Medical Meetings

Apr 17, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Upcoming Medical Meetings

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

Apr 1, 2025, 7:00 AM EDT - 1 year ago

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Mar 27, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 5, 2025, 7:00 AM EST - 1 year ago

CalciMedica Secures Credit Facility for Up to $32.5 Million

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Mar 4, 2025, 7:00 AM EST - 1 year ago

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

Jan 14, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 8:00 AM EST - 1 year ago

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Nov 13, 2024, 7:00 AM EST - 1 year ago

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

Nov 7, 2024, 7:00 AM EST - 1 year ago

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

CalciMedica Announces Pricing of Public Offering of Common Stock

Oct 30, 2024, 10:11 PM EDT - 1 year ago

CalciMedica Announces Pricing of Public Offering of Common Stock

CalciMedica Announces Proposed Public Offering of Common Stock

Oct 30, 2024, 4:50 PM EDT - 1 year ago

CalciMedica Announces Proposed Public Offering of Common Stock

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 30, 2024, 7:00 AM EDT - 1 year ago

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Oct 28, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2024, 4:10 PM EDT - 1 year ago

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Jul 9, 2024, 7:30 AM EDT - 1 year ago

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

Jul 8, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

CalciMedica Set to Join Russell Microcap® Index

Jul 1, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Set to Join Russell Microcap® Index

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 27, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 26, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

May 13, 2024, 4:05 PM EDT - 2 years ago

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Apr 24, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 28, 2024, 7:00 AM EDT - 2 years ago

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Mar 13, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 28, 2024, 6:57 PM EST - 2 years ago

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Feb 13, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 4:05 PM EST - 2 years ago

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CalciMedica Announces Private Placement of up to Approximately $55 Million

Jan 22, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces Private Placement of up to Approximately $55 Million

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Nov 2, 2023, 9:15 AM EDT - 2 years ago

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

CalciMedica Announces Upcoming Presentations and Events in September

Sep 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentations and Events in September

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Aug 31, 2023, 7:30 AM EDT - 2 years ago

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Aug 9, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Butterflies5
Butterflies5 Apr. 3 at 12:25 AM
$CALC Oppenheimer has a $10 price target reduced from $20 based upon an issue that's been proven to be incorrect. So why are we at $0.59?
0 · Reply
keokeostwiz
keokeostwiz Apr. 2 at 11:50 AM
$CALC Nothing has changed from the $7 handle before being HIT with unsubstantiated safety concerns during trial.......24% insider ownership consumed by seeking new finance agreement.....when news appears out of nowhere volume will surge and price will retrace suddenly.....facing June FDA acceptance of P3 trial design as expecting some kind of financial outcome before that crucial timeline.....the science is stellar and the pipeline loaded with outstanding candidates for development.....once finances secured CALC will reward shareholders handsomely and continue pursuit of pipeline development.....JMO
1 · Reply
Super_Marioo
Super_Marioo Apr. 1 at 5:23 PM
$CALC - nice upward stair pattern on daily chart. going up! let’s take the faster escalator next toward $1.
0 · Reply
OffComesTheShirt
OffComesTheShirt Apr. 1 at 3:20 PM
$CALC 11% Off Comes The Shirt
0 · Reply
pablo4
pablo4 Apr. 1 at 2:55 PM
$CALC just need that volume....then zoom, IMO.
0 · Reply
pablo4
pablo4 Mar. 31 at 7:03 PM
$CALC I have a feeling that volume is going to show up suddenly and price will loose. CALC closed its gap at .507 earlier today that was opened a couple of weeks or so back on the day of its ER that, along with earnings, disclosed that there were no safety issues found in the Kourage trial after all. IMO
0 · Reply
Butterflies5
Butterflies5 Mar. 31 at 1:12 AM
$CALC Oppenheimer lowers its target price from $20 down to $10 and we're trading at 52 cents Make it make sense
0 · Reply
keokeostwiz
keokeostwiz Mar. 30 at 4:24 PM
$CALC The liquidity problem will lead management toward a material event involving a finance deal, partnership or attracting a buyer for a valuable late stage pipeline as the company could get 150M - 200M in a sale event. Any of the above scenarios would present a serious problem for the shorts attempting to suppress price. Management is heavily invested and would not benefit from a heavily diluted cash raise leading rational decision toward securing a cash rich partner or sale . I believe management will protect their huge investment by securing a financial arrangement beneficial to shareholders and not reflecting a .54 cent share value.......JMO
0 · Reply
Eli18222
Eli18222 Mar. 27 at 4:41 PM
$CALC interesting actions recently
1 · Reply
Super_Marioo
Super_Marioo Mar. 26 at 7:58 PM
$CALC - not sure when but we are due for a MASSIVE pop for multiple reasons! $3 was the floor with before the FALSE safety issue that has now been confirmed. I will wait it out. $5-$10 was where it was heading with positive pipeline updates.
1 · Reply
keokeostwiz
keokeostwiz Mar. 26 at 4:02 PM
$CALC Ability to attract a partnership deal or secure a non dilutive finance deal will fuel the return to $5 as the science and pipeline are stellar....JMO
1 · Reply
swishnetster
swishnetster Mar. 26 at 2:02 PM
$CALC Any upcoming jolt that would send this stock much higher? $10 price trget doesn't seem acurate at all.
1 · Reply
Butterflies5
Butterflies5 Mar. 26 at 3:15 AM
$CALC no signs of intelligent life on this forum
1 · Reply
OffComesTheShirt
OffComesTheShirt Mar. 23 at 6:39 PM
$CALC 10% Off Comes The Shirt
0 · Reply
Super_Marioo
Super_Marioo Mar. 23 at 2:41 PM
$CALC - today is good but we need a trigger to pop us back to $4-$5. form 3s, 13g’s, etc or a positive pipeline update.
1 · Reply
OffComesTheShirt
OffComesTheShirt Mar. 23 at 2:37 PM
$CALC 10% Off Comes The Shirt
0 · Reply
Super_Marioo
Super_Marioo Mar. 20 at 9:48 PM
$CALC - I don’t see more than 10k volume at market close followed by 14k a few seconds into after hours that dropped us from 68c to 55c. anyway this drop is meaningless. it’s already at 64c.
2 · Reply
Don_Frye
Don_Frye Mar. 20 at 8:10 PM
$CALC shows 0.5776 close
0 · Reply
Don_Frye
Don_Frye Mar. 20 at 8:06 PM
$CALC market is brutal lately
0 · Reply
SUGONDEEZNUTS
SUGONDEEZNUTS Mar. 20 at 8:00 PM
$CALC damn who sold
0 · Reply
Super_Marioo
Super_Marioo Mar. 20 at 7:28 PM
$CALC - glass is half full. we are up 25.40% since last month. big boys want in and bought all the way to 90c. they buy in waves so price does not pop too high. next wave is coming and 90c will not be a resistance. have a good weekend guys. waiting for $2-$3.
1 · Reply
Cuatro2413
Cuatro2413 Mar. 20 at 4:04 PM
$CALC i bought more
0 · Reply